ICD-10-CM/PCS MS-DRG v37.2 Definitions Manual
Previous Page [Alt-p] Up a level [Alt-u] Next Page [Alt-n]
MDC 23 Factors Influencing Health Status & Other Contacts with Health Services
Assignment of Diagnosis Codes
Page 18 of 25
E0781 S01312D S1123XD S24151D S34103D S41119D S53025D S60448D S63250D S66391D S76209D S86092D S93512D S99249K T22552D T25112D T385X5D T43296A T472X3D T521X1D T63612D T82312D Z01110 Z48816 Z87798
T43296AUnderdosing of other antidepressants, initial encounter
T43296DUnderdosing of other antidepressants, subsequent encounter
T43296SUnderdosing of other antidepressants, sequela
T433X1DPoisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), subsequent encounter
T433X2DPoisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T433X3DPoisoning by phenothiazine antipsychotics and neuroleptics, assault, subsequent encounter
T433X4DPoisoning by phenothiazine antipsychotics and neuroleptics, undetermined, subsequent encounter
T433X5DAdverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter
T433X6AUnderdosing of phenothiazine antipsychotics and neuroleptics, initial encounter
T433X6DUnderdosing of phenothiazine antipsychotics and neuroleptics, subsequent encounter
T433X6SUnderdosing of phenothiazine antipsychotics and neuroleptics, sequela
T434X1DPoisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), subsequent encounter
T434X2DPoisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter
T434X3DPoisoning by butyrophenone and thiothixene neuroleptics, assault, subsequent encounter
T434X4DPoisoning by butyrophenone and thiothixene neuroleptics, undetermined, subsequent encounter
T434X5DAdverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter
T434X6AUnderdosing of butyrophenone and thiothixene neuroleptics, initial encounter
T434X6DUnderdosing of butyrophenone and thiothixene neuroleptics, subsequent encounter
T434X6SUnderdosing of butyrophenone and thiothixene neuroleptics, sequela
T43501DPoisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), subsequent encounter
T43502DPoisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43503DPoisoning by unspecified antipsychotics and neuroleptics, assault, subsequent encounter
T43504DPoisoning by unspecified antipsychotics and neuroleptics, undetermined, subsequent encounter
T43505DAdverse effect of unspecified antipsychotics and neuroleptics, subsequent encounter
T43506AUnderdosing of unspecified antipsychotics and neuroleptics, initial encounter
T43506DUnderdosing of unspecified antipsychotics and neuroleptics, subsequent encounter
T43506SUnderdosing of unspecified antipsychotics and neuroleptics, sequela
T43591DPoisoning by other antipsychotics and neuroleptics, accidental (unintentional), subsequent encounter
T43592DPoisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43593DPoisoning by other antipsychotics and neuroleptics, assault, subsequent encounter
T43594DPoisoning by other antipsychotics and neuroleptics, undetermined, subsequent encounter
T43595DAdverse effect of other antipsychotics and neuroleptics, subsequent encounter
T43596AUnderdosing of other antipsychotics and neuroleptics, initial encounter
T43596DUnderdosing of other antipsychotics and neuroleptics, subsequent encounter
T43596SUnderdosing of other antipsychotics and neuroleptics, sequela
T43601DPoisoning by unspecified psychostimulants, accidental (unintentional), subsequent encounter
T43602DPoisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter
T43603DPoisoning by unspecified psychostimulants, assault, subsequent encounter
T43604DPoisoning by unspecified psychostimulants, undetermined, subsequent encounter
T43605DAdverse effect of unspecified psychostimulants, subsequent encounter
T43606AUnderdosing of unspecified psychostimulants, initial encounter
T43606DUnderdosing of unspecified psychostimulants, subsequent encounter
T43606SUnderdosing of unspecified psychostimulants, sequela
T43611DPoisoning by caffeine, accidental (unintentional), subsequent encounter
T43612DPoisoning by caffeine, intentional self-harm, subsequent encounter
T43613DPoisoning by caffeine, assault, subsequent encounter
T43614DPoisoning by caffeine, undetermined, subsequent encounter
T43615DAdverse effect of caffeine, subsequent encounter
T43616AUnderdosing of caffeine, initial encounter
T43616DUnderdosing of caffeine, subsequent encounter
T43616SUnderdosing of caffeine, sequela
T43621DPoisoning by amphetamines, accidental (unintentional), subsequent encounter
T43622DPoisoning by amphetamines, intentional self-harm, subsequent encounter
T43623DPoisoning by amphetamines, assault, subsequent encounter
T43624DPoisoning by amphetamines, undetermined, subsequent encounter
T43625DAdverse effect of amphetamines, subsequent encounter
T43626AUnderdosing of amphetamines, initial encounter
T43626DUnderdosing of amphetamines, subsequent encounter
T43626SUnderdosing of amphetamines, sequela
T43631DPoisoning by methylphenidate, accidental (unintentional), subsequent encounter
T43632DPoisoning by methylphenidate, intentional self-harm, subsequent encounter
T43633DPoisoning by methylphenidate, assault, subsequent encounter
T43634DPoisoning by methylphenidate, undetermined, subsequent encounter
T43635DAdverse effect of methylphenidate, subsequent encounter
T43636AUnderdosing of methylphenidate, initial encounter
T43636DUnderdosing of methylphenidate, subsequent encounter
T43636SUnderdosing of methylphenidate, sequela
T43641DPoisoning by ecstasy, accidental (unintentional), subsequent encounter
T43642DPoisoning by ecstasy, intentional self-harm, subsequent encounter
T43643DPoisoning by ecstasy, assault, subsequent encounter
T43644DPoisoning by ecstasy, undetermined, subsequent encounter
T43691DPoisoning by other psychostimulants, accidental (unintentional), subsequent encounter
T43692DPoisoning by other psychostimulants, intentional self-harm, subsequent encounter
T43693DPoisoning by other psychostimulants, assault, subsequent encounter
T43694DPoisoning by other psychostimulants, undetermined, subsequent encounter
T43695DAdverse effect of other psychostimulants, subsequent encounter
T43696AUnderdosing of other psychostimulants, initial encounter
T43696DUnderdosing of other psychostimulants, subsequent encounter
T43696SUnderdosing of other psychostimulants, sequela
T438X1DPoisoning by other psychotropic drugs, accidental (unintentional), subsequent encounter
T438X2DPoisoning by other psychotropic drugs, intentional self-harm, subsequent encounter
T438X3DPoisoning by other psychotropic drugs, assault, subsequent encounter
T438X4DPoisoning by other psychotropic drugs, undetermined, subsequent encounter
T438X5DAdverse effect of other psychotropic drugs, subsequent encounter
T438X6AUnderdosing of other psychotropic drugs, initial encounter
T438X6DUnderdosing of other psychotropic drugs, subsequent encounter
T438X6SUnderdosing of other psychotropic drugs, sequela
T4391XDPoisoning by unspecified psychotropic drug, accidental (unintentional), subsequent encounter
T4392XDPoisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter
T4393XDPoisoning by unspecified psychotropic drug, assault, subsequent encounter
T4394XDPoisoning by unspecified psychotropic drug, undetermined, subsequent encounter
T4395XDAdverse effect of unspecified psychotropic drug, subsequent encounter
T4396XAUnderdosing of unspecified psychotropic drug, initial encounter
T4396XDUnderdosing of unspecified psychotropic drug, subsequent encounter
T4396XSUnderdosing of unspecified psychotropic drug, sequela
T440X1DPoisoning by anticholinesterase agents, accidental (unintentional), subsequent encounter
T440X2DPoisoning by anticholinesterase agents, intentional self-harm, subsequent encounter
T440X3DPoisoning by anticholinesterase agents, assault, subsequent encounter
T440X4DPoisoning by anticholinesterase agents, undetermined, subsequent encounter
T440X5DAdverse effect of anticholinesterase agents, subsequent encounter
T440X6AUnderdosing of anticholinesterase agents, initial encounter
T440X6DUnderdosing of anticholinesterase agents, subsequent encounter
T440X6SUnderdosing of anticholinesterase agents, sequela
T441X1DPoisoning by other parasympathomimetics [cholinergics], accidental (unintentional), subsequent encounter
T441X2DPoisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter
T441X3DPoisoning by other parasympathomimetics [cholinergics], assault, subsequent encounter
T441X4DPoisoning by other parasympathomimetics [cholinergics], undetermined, subsequent encounter
T441X5DAdverse effect of other parasympathomimetics [cholinergics], subsequent encounter
T441X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter
T441X6DUnderdosing of other parasympathomimetics [cholinergics], subsequent encounter
T441X6SUnderdosing of other parasympathomimetics [cholinergics], sequela
T442X1DPoisoning by ganglionic blocking drugs, accidental (unintentional), subsequent encounter
T442X2DPoisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter
T442X3DPoisoning by ganglionic blocking drugs, assault, subsequent encounter
T442X4DPoisoning by ganglionic blocking drugs, undetermined, subsequent encounter
T442X5DAdverse effect of ganglionic blocking drugs, subsequent encounter
T442X6AUnderdosing of ganglionic blocking drugs, initial encounter
T442X6DUnderdosing of ganglionic blocking drugs, subsequent encounter
T442X6SUnderdosing of ganglionic blocking drugs, sequela
T443X1DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), subsequent encounter
T443X2DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter
T443X3DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, subsequent encounter
T443X4DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, subsequent encounter
T443X5DAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T443X6AUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T443X6DUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T443X6SUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T444X1DPoisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
T444X2DPoisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter
T444X3DPoisoning by predominantly alpha-adrenoreceptor agonists, assault, subsequent encounter
T444X4DPoisoning by predominantly alpha-adrenoreceptor agonists, undetermined, subsequent encounter
T444X5DAdverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T444X6AUnderdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
T444X6DUnderdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T444X6SUnderdosing of predominantly alpha-adrenoreceptor agonists, sequela
T445X1DPoisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
T445X2DPoisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter
T445X3DPoisoning by predominantly beta-adrenoreceptor agonists, assault, subsequent encounter
T445X4DPoisoning by predominantly beta-adrenoreceptor agonists, undetermined, subsequent encounter
T445X5DAdverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
T445X6AUnderdosing of predominantly beta-adrenoreceptor agonists, initial encounter
T445X6DUnderdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter
T445X6SUnderdosing of predominantly beta-adrenoreceptor agonists, sequela
T446X1DPoisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
T446X2DPoisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T446X3DPoisoning by alpha-adrenoreceptor antagonists, assault, subsequent encounter
T446X4DPoisoning by alpha-adrenoreceptor antagonists, undetermined, subsequent encounter
T446X5DAdverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
T446X6AUnderdosing of alpha-adrenoreceptor antagonists, initial encounter
T446X6DUnderdosing of alpha-adrenoreceptor antagonists, subsequent encounter
T446X6SUnderdosing of alpha-adrenoreceptor antagonists, sequela
T447X1DPoisoning by beta-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
T447X2DPoisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T447X3DPoisoning by beta-adrenoreceptor antagonists, assault, subsequent encounter
T447X4DPoisoning by beta-adrenoreceptor antagonists, undetermined, subsequent encounter
T447X5DAdverse effect of beta-adrenoreceptor antagonists, subsequent encounter
T447X6AUnderdosing of beta-adrenoreceptor antagonists, initial encounter
T447X6DUnderdosing of beta-adrenoreceptor antagonists, subsequent encounter
T447X6SUnderdosing of beta-adrenoreceptor antagonists, sequela
T448X1DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), subsequent encounter
T448X2DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter
T448X3DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, subsequent encounter
T448X4DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, subsequent encounter
T448X5DAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T448X6AUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T448X6DUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T448X6SUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44901DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), subsequent encounter
T44902DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter
T44903DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, subsequent encounter
T44904DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, subsequent encounter
T44905DAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T44906AUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44906DUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T44906SUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44991DPoisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), subsequent encounter
T44992DPoisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter
T44993DPoisoning by other drug primarily affecting the autonomic nervous system, assault, subsequent encounter
T44994DPoisoning by other drug primarily affecting the autonomic nervous system, undetermined, subsequent encounter
T44995DAdverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44996AUnderdosing of other drug primarily affecting the autonomic nervous system, initial encounter
T44996DUnderdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44996SUnderdosing of other drug primarily affecting the autonomic nervous system, sequela
T450X1DPoisoning by antiallergic and antiemetic drugs, accidental (unintentional), subsequent encounter
T450X2DPoisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter
T450X3DPoisoning by antiallergic and antiemetic drugs, assault, subsequent encounter
T450X4DPoisoning by antiallergic and antiemetic drugs, undetermined, subsequent encounter
T450X5DAdverse effect of antiallergic and antiemetic drugs, subsequent encounter
T450X6AUnderdosing of antiallergic and antiemetic drugs, initial encounter
T450X6DUnderdosing of antiallergic and antiemetic drugs, subsequent encounter
T450X6SUnderdosing of antiallergic and antiemetic drugs, sequela
T451X1DPoisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), subsequent encounter
T451X2DPoisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, subsequent encounter
T451X3DPoisoning by antineoplastic and immunosuppressive drugs, assault, subsequent encounter
T451X4DPoisoning by antineoplastic and immunosuppressive drugs, undetermined, subsequent encounter
T451X5DAdverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T451X6AUnderdosing of antineoplastic and immunosuppressive drugs, initial encounter
T451X6DUnderdosing of antineoplastic and immunosuppressive drugs, subsequent encounter
T451X6SUnderdosing of antineoplastic and immunosuppressive drugs, sequela
T452X1DPoisoning by vitamins, accidental (unintentional), subsequent encounter
T452X2DPoisoning by vitamins, intentional self-harm, subsequent encounter
T452X3DPoisoning by vitamins, assault, subsequent encounter
T452X4DPoisoning by vitamins, undetermined, subsequent encounter
T452X5DAdverse effect of vitamins, subsequent encounter
T452X6AUnderdosing of vitamins, initial encounter
T452X6DUnderdosing of vitamins, subsequent encounter
T452X6SUnderdosing of vitamins, sequela
T453X1DPoisoning by enzymes, accidental (unintentional), subsequent encounter
T453X2DPoisoning by enzymes, intentional self-harm, subsequent encounter
T453X3DPoisoning by enzymes, assault, subsequent encounter
T453X4DPoisoning by enzymes, undetermined, subsequent encounter
T453X5DAdverse effect of enzymes, subsequent encounter
T453X6AUnderdosing of enzymes, initial encounter
T453X6DUnderdosing of enzymes, subsequent encounter
T453X6SUnderdosing of enzymes, sequela
T454X1DPoisoning by iron and its compounds, accidental (unintentional), subsequent encounter
T454X2DPoisoning by iron and its compounds, intentional self-harm, subsequent encounter
T454X3DPoisoning by iron and its compounds, assault, subsequent encounter
T454X4DPoisoning by iron and its compounds, undetermined, subsequent encounter
T454X5DAdverse effect of iron and its compounds, subsequent encounter
T454X6AUnderdosing of iron and its compounds, initial encounter
T454X6DUnderdosing of iron and its compounds, subsequent encounter
T454X6SUnderdosing of iron and its compounds, sequela
T45511DPoisoning by anticoagulants, accidental (unintentional), subsequent encounter
T45512DPoisoning by anticoagulants, intentional self-harm, subsequent encounter
T45513DPoisoning by anticoagulants, assault, subsequent encounter
T45514DPoisoning by anticoagulants, undetermined, subsequent encounter
T45515DAdverse effect of anticoagulants, subsequent encounter
T45516AUnderdosing of anticoagulants, initial encounter
T45516DUnderdosing of anticoagulants, subsequent encounter
T45516SUnderdosing of anticoagulants, sequela
T45521DPoisoning by antithrombotic drugs, accidental (unintentional), subsequent encounter
T45522DPoisoning by antithrombotic drugs, intentional self-harm, subsequent encounter
T45523DPoisoning by antithrombotic drugs, assault, subsequent encounter
T45524DPoisoning by antithrombotic drugs, undetermined, subsequent encounter
T45525DAdverse effect of antithrombotic drugs, subsequent encounter
T45526AUnderdosing of antithrombotic drugs, initial encounter
T45526DUnderdosing of antithrombotic drugs, subsequent encounter
T45526SUnderdosing of antithrombotic drugs, sequela
T45601DPoisoning by unspecified fibrinolysis-affecting drugs, accidental (unintentional), subsequent encounter
T45602DPoisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter
T45603DPoisoning by unspecified fibrinolysis-affecting drugs, assault, subsequent encounter
T45604DPoisoning by unspecified fibrinolysis-affecting drugs, undetermined, subsequent encounter
T45605DAdverse effect of unspecified fibrinolysis-affecting drugs, subsequent encounter
T45606AUnderdosing of unspecified fibrinolysis-affecting drugs, initial encounter
T45606DUnderdosing of unspecified fibrinolysis-affecting drugs, subsequent encounter
T45606SUnderdosing of unspecified fibrinolysis-affecting drugs, sequela
T45611DPoisoning by thrombolytic drug, accidental (unintentional), subsequent encounter
T45612DPoisoning by thrombolytic drug, intentional self-harm, subsequent encounter
T45613DPoisoning by thrombolytic drug, assault, subsequent encounter
T45614DPoisoning by thrombolytic drug, undetermined, subsequent encounter
T45615DAdverse effect of thrombolytic drugs, subsequent encounter
T45616AUnderdosing of thrombolytic drugs, initial encounter
T45616DUnderdosing of thrombolytic drugs, subsequent encounter
T45616SUnderdosing of thrombolytic drugs, sequela
T45621DPoisoning by hemostatic drug, accidental (unintentional), subsequent encounter
T45622DPoisoning by hemostatic drug, intentional self-harm, subsequent encounter
T45623DPoisoning by hemostatic drug, assault, subsequent encounter
T45624DPoisoning by hemostatic drug, undetermined, subsequent encounter
T45625DAdverse effect of hemostatic drug, subsequent encounter
T45626AUnderdosing of hemostatic drugs, initial encounter
T45626DUnderdosing of hemostatic drugs, subsequent encounter
T45626SUnderdosing of hemostatic drugs, sequela
T45691DPoisoning by other fibrinolysis-affecting drugs, accidental (unintentional), subsequent encounter
T45692DPoisoning by other fibrinolysis-affecting drugs, intentional self-harm, subsequent encounter
T45693DPoisoning by other fibrinolysis-affecting drugs, assault, subsequent encounter
T45694DPoisoning by other fibrinolysis-affecting drugs, undetermined, subsequent encounter
T45695DAdverse effect of other fibrinolysis-affecting drugs, subsequent encounter
T45696AUnderdosing of other fibrinolysis-affecting drugs, initial encounter
T45696DUnderdosing of other fibrinolysis-affecting drugs, subsequent encounter
T45696SUnderdosing of other fibrinolysis-affecting drugs, sequela
T457X1DPoisoning by anticoagulant antagonists, vitamin K and other coagulants, accidental (unintentional), subsequent encounter
T457X2DPoisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, subsequent encounter
T457X3DPoisoning by anticoagulant antagonists, vitamin K and other coagulants, assault, subsequent encounter
T457X4DPoisoning by anticoagulant antagonists, vitamin K and other coagulants, undetermined, subsequent encounter
T457X5DAdverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter
T457X6AUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, initial encounter
T457X6DUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, subsequent encounter
T457X6SUnderdosing of anticoagulant antagonist, vitamin K and other coagulants, sequela
T458X1DPoisoning by other primarily systemic and hematological agents, accidental (unintentional), subsequent encounter
T458X2DPoisoning by other primarily systemic and hematological agents, intentional self-harm, subsequent encounter
T458X3DPoisoning by other primarily systemic and hematological agents, assault, subsequent encounter
T458X4DPoisoning by other primarily systemic and hematological agents, undetermined, subsequent encounter
T458X5DAdverse effect of other primarily systemic and hematological agents, subsequent encounter
T458X6AUnderdosing of other primarily systemic and hematological agents, initial encounter
T458X6DUnderdosing of other primarily systemic and hematological agents, subsequent encounter
T458X6SUnderdosing of other primarily systemic and hematological agents, sequela
T4591XDPoisoning by unspecified primarily systemic and hematological agent, accidental (unintentional), subsequent encounter
T4592XDPoisoning by unspecified primarily systemic and hematological agent, intentional self-harm, subsequent encounter
T4593XDPoisoning by unspecified primarily systemic and hematological agent, assault, subsequent encounter
T4594XDPoisoning by unspecified primarily systemic and hematological agent, undetermined, subsequent encounter
T4595XDAdverse effect of unspecified primarily systemic and hematological agent, subsequent encounter
T4596XAUnderdosing of unspecified primarily systemic and hematological agent, initial encounter
T4596XDUnderdosing of unspecified primarily systemic and hematological agent, subsequent encounter
T4596XSUnderdosing of unspecified primarily systemic and hematological agent, sequela
T460X1DPoisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), subsequent encounter
T460X2DPoisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter
T460X3DPoisoning by cardiac-stimulant glycosides and drugs of similar action, assault, subsequent encounter
T460X4DPoisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, subsequent encounter
T460X5DAdverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
T460X6AUnderdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T460X6DUnderdosing of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
T460X6SUnderdosing of cardiac-stimulant glycosides and drugs of similar action, sequela
T461X1DPoisoning by calcium-channel blockers, accidental (unintentional), subsequent encounter
T461X2DPoisoning by calcium-channel blockers, intentional self-harm, subsequent encounter
T461X3DPoisoning by calcium-channel blockers, assault, subsequent encounter
T461X4DPoisoning by calcium-channel blockers, undetermined, subsequent encounter
T461X5DAdverse effect of calcium-channel blockers, subsequent encounter
T461X6AUnderdosing of calcium-channel blockers, initial encounter
T461X6DUnderdosing of calcium-channel blockers, subsequent encounter
T461X6SUnderdosing of calcium-channel blockers, sequela
T462X1DPoisoning by other antidysrhythmic drugs, accidental (unintentional), subsequent encounter
T462X2DPoisoning by other antidysrhythmic drugs, intentional self-harm, subsequent encounter
T462X3DPoisoning by other antidysrhythmic drugs, assault, subsequent encounter
T462X4DPoisoning by other antidysrhythmic drugs, undetermined, subsequent encounter
T462X5DAdverse effect of other antidysrhythmic drugs, subsequent encounter
T462X6AUnderdosing of other antidysrhythmic drugs, initial encounter
T462X6DUnderdosing of other antidysrhythmic drugs, subsequent encounter
T462X6SUnderdosing of other antidysrhythmic drugs, sequela
T463X1DPoisoning by coronary vasodilators, accidental (unintentional), subsequent encounter
T463X2DPoisoning by coronary vasodilators, intentional self-harm, subsequent encounter
T463X3DPoisoning by coronary vasodilators, assault, subsequent encounter
T463X4DPoisoning by coronary vasodilators, undetermined, subsequent encounter
T463X5DAdverse effect of coronary vasodilators, subsequent encounter
T463X6AUnderdosing of coronary vasodilators, initial encounter
T463X6DUnderdosing of coronary vasodilators, subsequent encounter
T463X6SUnderdosing of coronary vasodilators, sequela
T464X1DPoisoning by angiotensin-converting-enzyme inhibitors, accidental (unintentional), subsequent encounter
T464X2DPoisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, subsequent encounter
T464X3DPoisoning by angiotensin-converting-enzyme inhibitors, assault, subsequent encounter
T464X4DPoisoning by angiotensin-converting-enzyme inhibitors, undetermined, subsequent encounter
T464X5DAdverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter
T464X6AUnderdosing of angiotensin-converting-enzyme inhibitors, initial encounter
T464X6DUnderdosing of angiotensin-converting-enzyme inhibitors, subsequent encounter
T464X6SUnderdosing of angiotensin-converting-enzyme inhibitors, sequela
T465X1DPoisoning by other antihypertensive drugs, accidental (unintentional), subsequent encounter
T465X2DPoisoning by other antihypertensive drugs, intentional self-harm, subsequent encounter
T465X3DPoisoning by other antihypertensive drugs, assault, subsequent encounter
T465X4DPoisoning by other antihypertensive drugs, undetermined, subsequent encounter
T465X5DAdverse effect of other antihypertensive drugs, subsequent encounter
T465X6AUnderdosing of other antihypertensive drugs, initial encounter
T465X6DUnderdosing of other antihypertensive drugs, subsequent encounter
T465X6SUnderdosing of other antihypertensive drugs, sequela
T466X1DPoisoning by antihyperlipidemic and antiarteriosclerotic drugs, accidental (unintentional), subsequent encounter
T466X2DPoisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, subsequent encounter
T466X3DPoisoning by antihyperlipidemic and antiarteriosclerotic drugs, assault, subsequent encounter
T466X4DPoisoning by antihyperlipidemic and antiarteriosclerotic drugs, undetermined, subsequent encounter
T466X5DAdverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
T466X6AUnderdosing of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter
T466X6DUnderdosing of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter
T466X6SUnderdosing of antihyperlipidemic and antiarteriosclerotic drugs, sequela
T467X1DPoisoning by peripheral vasodilators, accidental (unintentional), subsequent encounter
T467X2DPoisoning by peripheral vasodilators, intentional self-harm, subsequent encounter
T467X3DPoisoning by peripheral vasodilators, assault, subsequent encounter
T467X4DPoisoning by peripheral vasodilators, undetermined, subsequent encounter
T467X5DAdverse effect of peripheral vasodilators, subsequent encounter
T467X6AUnderdosing of peripheral vasodilators, initial encounter
T467X6DUnderdosing of peripheral vasodilators, subsequent encounter
T467X6SUnderdosing of peripheral vasodilators, sequela
T468X1DPoisoning by antivaricose drugs, including sclerosing agents, accidental (unintentional), subsequent encounter
T468X2DPoisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, subsequent encounter
T468X3DPoisoning by antivaricose drugs, including sclerosing agents, assault, subsequent encounter
T468X4DPoisoning by antivaricose drugs, including sclerosing agents, undetermined, subsequent encounter
T468X5DAdverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter
T468X6AUnderdosing of antivaricose drugs, including sclerosing agents, initial encounter
T468X6DUnderdosing of antivaricose drugs, including sclerosing agents, subsequent encounter
T468X6SUnderdosing of antivaricose drugs, including sclerosing agents, sequela
T46901DPoisoning by unspecified agents primarily affecting the cardiovascular system, accidental (unintentional), subsequent encounter
T46902DPoisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter
T46903DPoisoning by unspecified agents primarily affecting the cardiovascular system, assault, subsequent encounter
T46904DPoisoning by unspecified agents primarily affecting the cardiovascular system, undetermined, subsequent encounter
T46905DAdverse effect of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
T46906AUnderdosing of unspecified agents primarily affecting the cardiovascular system, initial encounter
T46906DUnderdosing of unspecified agents primarily affecting the cardiovascular system, subsequent encounter
T46906SUnderdosing of unspecified agents primarily affecting the cardiovascular system, sequela
T46991DPoisoning by other agents primarily affecting the cardiovascular system, accidental (unintentional), subsequent encounter
T46992DPoisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, subsequent encounter
T46993DPoisoning by other agents primarily affecting the cardiovascular system, assault, subsequent encounter
T46994DPoisoning by other agents primarily affecting the cardiovascular system, undetermined, subsequent encounter
T46995DAdverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter
T46996AUnderdosing of other agents primarily affecting the cardiovascular system, initial encounter
T46996DUnderdosing of other agents primarily affecting the cardiovascular system, subsequent encounter
T46996SUnderdosing of other agents primarily affecting the cardiovascular system, sequela
T470X1DPoisoning by histamine H2-receptor blockers, accidental (unintentional), subsequent encounter
T470X2DPoisoning by histamine H2-receptor blockers, intentional self-harm, subsequent encounter
T470X3DPoisoning by histamine H2-receptor blockers, assault, subsequent encounter
T470X4DPoisoning by histamine H2-receptor blockers, undetermined, subsequent encounter
T470X5DAdverse effect of histamine H2-receptor blockers, subsequent encounter
T470X6AUnderdosing of histamine H2-receptor blockers, initial encounter
T470X6DUnderdosing of histamine H2-receptor blockers, subsequent encounter
T470X6SUnderdosing of histamine H2-receptor blockers, sequela
T471X1DPoisoning by other antacids and anti-gastric-secretion drugs, accidental (unintentional), subsequent encounter
T471X2DPoisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, subsequent encounter
T471X3DPoisoning by other antacids and anti-gastric-secretion drugs, assault, subsequent encounter
T471X4DPoisoning by other antacids and anti-gastric-secretion drugs, undetermined, subsequent encounter
T471X5DAdverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter
T471X6AUnderdosing of other antacids and anti-gastric-secretion drugs, initial encounter
T471X6DUnderdosing of other antacids and anti-gastric-secretion drugs, subsequent encounter
T471X6SUnderdosing of other antacids and anti-gastric-secretion drugs, sequela
T472X1DPoisoning by stimulant laxatives, accidental (unintentional), subsequent encounter
T472X2DPoisoning by stimulant laxatives, intentional self-harm, subsequent encounter



Centers for Medicare & Medicaid Services, 7500 Security Boulevard Baltimore, MD 21244
09 Jul 2020 15:51:46
CMS, code-revision=268, description-revision=1285